Jacobs Levy Equity Management’s Ligand Pharmaceuticals LGND Stock Holding History

Jacobs Levy Equity Management's LGND Position: Q2 2026 in Review

Jacobs Levy Equity Management reduced its Ligand Pharmaceuticals (LGND) stake by 41% in Q2 2026, selling an estimated $2M and leaving 12,049 shares worth $3.81M. The position accounts for 0.01% of the portfolio, ranked #478.

Jacobs Levy Equity Management first reported a position in LGND in Q1 2023 and has held it in 10 quarters since. The position peaked at $24M in Q4 2025. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

• Jacobs Levy Equity Management held 12,049 shares of Ligand Pharmaceuticals worth $3.81M as of Q2 2026.
• Jacobs Levy Equity Management sold 8,480 Ligand Pharmaceuticals shares in Q2 2026, an estimated $2M.
• Ligand Pharmaceuticals made up 0.01% of Jacobs Levy Equity Management's portfolio in Q2 2026, its #478 holding.
• Jacobs Levy Equity Management first reported a position in Ligand Pharmaceuticals in Q1 2023 and has held it in 10 quarters since.
• Jacobs Levy Equity Management's Ligand Pharmaceuticals position peaked at $24M in Q4 2025.
• 414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2026, filed 14 Aug 2026.